Indaptus Therapeutics
Monday, February 26, 2024
Uris
Oncology
Indaptus Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 1 clinical trial.
State
NY
Country
United States
Website
https://indaptusrx.com
CEO/Top Company Official
Jeffrey Meckler
Lead Product in Development
Decoy20
Development Phase of Primary Product
Phase I
Number Of Unlicensed Products
3
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}